---
title: "Beyond the Noise: How Hong Kong's 'Other' Stocks Are Winning Through Quiet Reinvention"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301685862.md"
description: "Xiaocaiyuan's 24% holiday traffic growth, China Nonferrous Mining's copper-driven profit surge, and Hutchmed's biotech breakthrough exemplify how Hong Kong's 'Other' sector stocks are rewriting narratives through operational pivots rather than market hype."
datetime: "2026-10-13T09:25:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301685862.md)
  - [en](https://longbridge.com/en/news/301685862.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301685862.md)
generator: "portal-rs"
---

# Beyond the Noise: How Hong Kong's 'Other' Stocks Are Winning Through Quiet Reinvention

When Xiaocaiyuan’s dining tables filled with 2.7 million holiday patrons, China Nonferrous Mining’s copper cathodes were powering AI data centers halfway across the globe. Hong Kong’s eclectic ‘Other’ sector defies categorization yet reveals telling patterns: consumer resilience, resource scarcity, and biotech pivots are reshaping narratives. The restaurant chain (2273.HK) saw same-store traffic rise 6.2% during Golden Week despite price cuts, while its 88-member program now drives 27% of revenue. At China Nonferrous Mining (1258.HK), soaring copper prices propelled first-half profits up 64.7% as Deutsche Bank warned global inventories hit historic lows. Hutchmed (0013.HK) secured a USD 1.3 billion GSK deal for its colorectal cancer drug, fueling a 51% rebound from June lows.

Traditional sectors show contrasting trajectories. Gushengtang (2500.HK) continues share buybacks amid steady growth in traditional Chinese medicine services, while Dahon Tech (2515.HK) struggles with fading recreational vehicle demand. Venus Medtech (2543.HK) navigated domestic pricing pressures by securing RMB 500 million in state-backed financing, shifting 37.4% of revenue overseas. Meanwhile, construction contractor 0999.HK faces volatile quarterly results, Singaporean bakery-chain operator 8527.HK reports sequential revenue declines, and 3677.HK remains obscured by sparse disclosures – a microcosm of Hong Kong’s fragmented small-cap landscape where fundamentals often outpace market attention.

### Related Stocks

- [02273.HK](https://longbridge.com/en/quote/02273.HK.md)
- [01258.HK](https://longbridge.com/en/quote/01258.HK.md)
- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)
- [02500.HK](https://longbridge.com/en/quote/02500.HK.md)
- [02515.HK](https://longbridge.com/en/quote/02515.HK.md)
- [02543.HK](https://longbridge.com/en/quote/02543.HK.md)
- [00999.HK](https://longbridge.com/en/quote/00999.HK.md)
- [08527.HK](https://longbridge.com/en/quote/08527.HK.md)
- [03677.HK](https://longbridge.com/en/quote/03677.HK.md)

## Related News & Research

- [Xiaocaiyuan Schedules Board Meeting to Consider Special Dividend](https://longbridge.com/en/news/305828179.md)
- [UBS: HUTCHMED  Sovleplenib Approved in China for ITP and wAIHA Treatment, Positive and Better Than Expected](https://longbridge.com/en/news/306233318.md)
- [HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS® | HCM Stock News](https://longbridge.com/en/news/305611428.md)
- [Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable](https://longbridge.com/en/news/306083646.md)
- [Gushengtang Agrees to Acquire Control of Four Clinics](https://longbridge.com/en/news/304470887.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**